442 related articles for article (PubMed ID: 24358223)
21. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
22. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
Mock U; Nickolay L; Philip B; Cheung GW; Zhan H; Johnston ICD; Kaiser AD; Peggs K; Pule M; Thrasher AJ; Qasim W
Cytotherapy; 2016 Aug; 18(8):1002-1011. PubMed ID: 27378344
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
24. Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.
Orlando D; Miele E; De Angelis B; Guercio M; Boffa I; Sinibaldi M; Po A; Caruana I; Abballe L; Carai A; Caruso S; Camera A; Moseley A; Hagedoorn RS; Heemskerk MHM; Giangaspero F; Mastronuzzi A; Ferretti E; Locatelli F; Quintarelli C
Cancer Res; 2018 Jun; 78(12):3337-3349. PubMed ID: 29615432
[TBL] [Abstract][Full Text] [Related]
25. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
26. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
27. Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.
Chen F; Fan C; Gu X; Zhang H; Liu Q; Gao X; Lu J; He B; Lai X
Med Sci Monit; 2015 Jul; 21():2110-5. PubMed ID: 26195067
[TBL] [Abstract][Full Text] [Related]
28. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
[TBL] [Abstract][Full Text] [Related]
29. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
30. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
[TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Till BG; Jensen MC; Wang J; Chen EY; Wood BL; Greisman HA; Qian X; James SE; Raubitschek A; Forman SJ; Gopal AK; Pagel JM; Lindgren CG; Greenberg PD; Riddell SR; Press OW
Blood; 2008 Sep; 112(6):2261-71. PubMed ID: 18509084
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
[TBL] [Abstract][Full Text] [Related]
33. Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells.
Xu Y; Li S; Wang Y; Liu J; Mao X; Xing H; Tian Z; Tang K; Liao X; Rao Q; Xiong D; Wang M; Wang J
Hum Gene Ther; 2019 Apr; 30(4):497-510. PubMed ID: 30381966
[TBL] [Abstract][Full Text] [Related]
34. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
[TBL] [Abstract][Full Text] [Related]
35. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
[TBL] [Abstract][Full Text] [Related]
36. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
37. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
38. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
39. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
40. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
Frey NV; Porter DL
Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]